STOCK TITAN
  1. Home
  2. News
  3. REGN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.

The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.

Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.

Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.

For more information, visit Regeneron Pharmaceuticals.

News

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Rhea-AI Summary
FDA approves EYLEA HD for wAMD, DME, and DR treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

Rhea-AI Summary
Regeneron Pharmaceuticals receives FDA approval for Veopoz for the treatment of CHAPLE disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
fda approval
-
News

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Rhea-AI Summary
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for odronextamab, an investigational CD20xCD3 bispecific antibody, for the treatment of relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). Odronextamab has received Orphan Drug Designation for FL and DLBCL. The MAA is supported by data from Phase 1 and Phase 2 trials, and Regeneron is conducting a Phase 3 development program to further investigate odronextamab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
News

Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive, two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (wAMD). The study showed that 88% of patients were on a ≥12-week dosing interval at the end of two years, with 78% maintaining ≥12-week intervals throughout the study period. Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
News

Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

Rhea-AI Summary
Regeneron Pharmaceuticals and Decibel Therapeutics have announced a definitive agreement for the acquisition of Decibel by Regeneron. The acquisition will be at a price of $4.00 per share of Decibel common stock, with an additional non-tradeable contingent value right (CVR) of up to $3.50 per share. The proposed acquisition values Decibel at a total equity value of approximately $109 million, and up to approximately $213 million if certain milestones are achieved. Decibel's lead investigational gene therapy, DB-OTO, is currently in its first clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
acquisition
-
News

Regeneron Reports Second Quarter 2023 Financial and Operating Results

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an 11% increase in Q2 2023 revenues to $3.16 billion, with Dupixent® global net sales up 33% to $2.79 billion. EYLEA® U.S. net sales were $1.50 billion. Q2 2023 GAAP diluted EPS was $8.50 and non-GAAP diluted EPS was $10.24. Aflibercept 8 mg BLA decision is expected in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
earnings
News

Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces winners of the 11th annual Regeneron Prize for Creative Innovation honoring exceptional talent and originality in biomedical research. Winners receive cash prizes to pursue groundbreaking research projects in the field of biomedical science, totaling $140,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
News

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

Rhea-AI Summary
Regeneron Pharmaceuticals announces positive two-year results from the PHOTON trial investigating aflibercept 8 mg in patients with diabetic macular edema (DME). 89% and 84% of patients maintained ≥12-week and ≥16-week dosing intervals, respectively, throughout the two-year period. 44% of patients met the criteria for ≥20-week dosing intervals at week 96. The safety profile of aflibercept 8 mg remained consistent with previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences earnings
News

Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
none

FAQ

What types of diseases does Regeneron Pharmaceuticals focus on?

Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

What are some of Regeneron's key products?

Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.

Who are some of Regeneron's notable collaborators?

Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.

What recent financial steps has Regeneron taken?

Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.

How does Regeneron leverage genetic medicine?

Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.

What is the significance of Eylea in Regeneron's product portfolio?

Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.

What advancements has Regeneron made in gene therapy?

Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.

What is Dupixent used for?

Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.

What technologies does Regeneron use for drug development?

Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.

How does Regeneron contribute to scientific discovery?

Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.

Stock REGN logo
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

#102 Ranked by Market Cap
N/A Ranked by Dividends

REGN Stock Data

119.17B
108.37M
1.6%
89.92%
1.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TARRYTOWN